InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: misiu143 post# 1438

Wednesday, 04/13/2016 8:25:58 PM

Wednesday, April 13, 2016 8:25:58 PM

Post# of 233768
Yes because if the company proves that it can reduce viral load greater than standard of care treatment from Gilead and for a longer period of time then Gilead will definitely be a buyer to protect its 44% HIV yearly revenue stream. I don't think that Gilead would want to lose its 44% revenue stream to a small-cap biotech company.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News